Platelet Mediated Complement Activation
The complement system comprises a series of proteases and inhibitors that are activated in cascade-like fashion during host defense (Makrides 1998). A growing body of evidence supports the hypothesis that immune mechanisms, including complement activation, are involved in inflammatory conditions associated with vascular injury (Acostan et al. 2004; Giannakopoulos et al. 2007), and disseminated intravascular coagulation associated with massive trauma (Huber-Lang, this volume). We propose that platelets and platelet derived microparticles focus complement to sites of vascular injury where regulated complement activation participates in clearing terminally activated platelets and microparticles from the circulation, and dysregulated complement activation contributes to inflammation and thrombosis. Given the central role of platelets in hemostasis and thrombosis, it is not surprising that activated complement components have been demonstrated in many types of atherosclerotic and thrombotic vascular lesions (Torzewsjki et al. 2007; Niculescu et al. 2004).
KeywordsComplement Activation Complement Component Classical Complement Pathway Terminal Complement Complex Induce Tissue Factor Expression
This work was supported in part by grants HL67211 (EIBP) and AI060866 (BG) from the National Institutes of Health, and an American Heart Association Heritage Affiliate postdoctoral award # 0625900T (WY).
- George, J.N., Pickett, E.B., Saucerman, S., McEver, R.P., Kunicki, T.J., Kieffer, N., and Newman, P.J. (1986) Platelet surface glycoproteins. Studies on resting and activated platelets and platelet membrane microparticles in normal subjects, and observations in patients during adult respiratory distress syndrome and cardiac surgery. J. Clin. Invest. 78, 340–348PubMedCrossRefGoogle Scholar
- Huber-Lang, M., Sarma, J.V., Zetoune, F.S., Rittirsch, D., Neff, T.A., McGuire, S.R., Lambris, J.D., Warner, R.L., Flierl, M.A., Hoesel, L.M., Gebhard, F., Younger, J.G., Drouin, S.M., Wetsel, R.A., and Ward, P.A. (2006) Generation of C5a in the absence of C3: a new complement activation pathway. Nat. Med. 12, 682–687PubMedCrossRefGoogle Scholar
- Kaplan, A.P., Silverberg, M., and Ghebrehiwet, B. (1986) The intrinsic coagulation/kinin pathway – the classical complement pathway and their interactions. Adv. Exp. Med. Biol. 198, 1311–1325Google Scholar
- Mack, W.J., Sughrue, M.W., Ducruet, A.F., Mocco, J., Sosunov, S.A., Hassid, B.G., Silverberg, J.Z., Ten, V.S., Pinsky, D.J., and Connolly Jr., E.S. (2006). Temporal pattern of C1q deposition after transient focal cerebral ischemia. Wiley InterScience (www.interscience.wiley.com( doi:10, 1002/jnr.20775
- Makrides, S.C. (1998) Therapeutic inhibition of the complement system. Pharmacol. Rev. 150, 59–87Google Scholar
- Patel, S., Thelander, E.M., Hernandez, M., Montenegro, J., Hassing, H., Burton, C., Mundt, S., Hermanowski-Vosatka, A., Wright, S.D., Chao, Y.S., and Detmers, P.A. (2001) ApoE. −/− mice develop atherosclerosis in the absence of complement component C5. Biochem. Biophys Res. Commun. 286, 164–170Google Scholar
- Peerschke, E.I.B., Murphy, T.K., and Ghebrehiwet, B. (2003) Activation-dependent surface expression of gC1qR/p33 on human blood platelets. Thromb. Haemost. 90, 331–339Google Scholar
- Peerschke , E.I.B., Yin, W., Alpert, D.R., Salmon, J.E., Roubey, R.A.S., and Ghebrehiwet, B. (2007). Enhanced serum complement activation on platelets is associated with arterial thrombosis in patients with systemic lupus erythematosus (SLE) and antiphospholipid antibodies (aPL) (abstract). Blood 110, 448aGoogle Scholar
- Seidl, W.S., Exner, M., Amighi, J., Kastl, S.P., Zorn, G., Maurer, G., Wagner, O., Huber, K., Minar, E., Wojta, J., and Schillinger, M. (2005) Complement component C5a predicts future cardiovascular events in patients with advanced atherosclerosis. Europ. Heart.. J26, 2294–2299CrossRefGoogle Scholar
- Shenghe, C., and Davie III, A.E. (2003) Complement regulatory protein C1 inhibitor binds to selectins and interferes with endothelial-leukocyte adhesion. J. Immunol. 171, 4786–4791Google Scholar